1 |
MAPK14
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
2 |
MAPK14
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
3 |
IFNA1
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
4 |
IFNA1
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
5 |
IFNA2
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
6 |
IFNA2
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
7 |
IFNA4
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
8 |
IFNA4
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
9 |
IFNA5
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
10 |
IFNA5
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
11 |
IFNA6
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
12 |
IFNA6
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
13 |
IFNA7
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
14 |
IFNA7
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
15 |
IFNA8
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
16 |
IFNA8
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
17 |
IFNA10
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
18 |
IFNA10
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
19 |
IFNA13
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
20 |
IFNA13
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
21 |
IFNA14
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
22 |
IFNA14
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
23 |
IFNA16
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
24 |
IFNA16
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
25 |
IFNA17
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
26 |
IFNA17
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
27 |
IFNA21
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
28 |
IFNA21
| 6件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
29 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
30 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
31 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
32 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
33 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
34 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
35 |
IFNAR1
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 2件: 46 46, 49 |
36 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
37 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
38 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
39 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
40 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
41 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
42 |
IFNAR2
| 5件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 2件: 46 46, 49 |
43 |
IL1B
| 16件: Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
44 |
IL1B
| 16件: Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D06635
D06635
|
Rilonacept
| 4件: 51 51, 106, 107, 266 |
45 |
IL1B
| 16件: Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D09315
D09315
|
Canakinumab
| 10件: 46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 |
46 |
IL1B
| 16件: Osteoclast differentiation Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Rheumatoid arthritis | D09911
D09911
|
Gevokizumab
| 4件: 41 41, 50, 56, 269 |
47 |
IL6
| 17件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
48 |
IL6
| 17件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
49 |
IL6
| 17件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D09669
D09669
|
Siltuximab
| 2件: 28 28, 331 |
50 |
IL6
| 17件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis | D10080
D10080
|
Sirukumab
| 2件: 41 41, 46 |
51 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09959
D09959
|
Ruxolitinib
| 1件: 228 228 |
52 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
53 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10308
D10308
|
Baricitinib
| 13件: 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
54 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10653
D10653
|
Peficitinib
| 1件: 46 46 |
55 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10871
D10871
|
Filgotinib
| 6件: 46 46, 53, 96, 97, 222, 271 |
56 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10944
D10944
|
Itacitinib
| 5件: 46 46, 51, 60, 97, 228 |
57 |
JAK1
| 12件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10994
D10994
|
Upadacitinib
| 8件: 40 40, 41, 46, 49, 96, 97, 107, 271 |
58 |
NFKB1
| 29件: Ras signaling pathway Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D01146
D01146
|
Iguratimod
| 4件: 46 46, 51, 53, 271 |
59 |
PRKCD
| 5件: Vascular smooth muscle contraction Vascular smooth muscle contraction, NOD-like receptor signaling pathway, Type II diabetes mellitus, Prion disease, Shigellosis | D09671
D09671
|
Sotrastaurin
| 1件: 97 97 |
60 |
MAPK11
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
61 |
MAPK11
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
62 |
MAPK13
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
63 |
MAPK13
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
64 |
BCL2
| 15件: Platinum drug resistance Platinum drug resistance, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Prostate cancer, Small cell lung cancer | D10679
D10679
|
Venetoclax
| 1件: 28 28 |
65 |
RELA
| 29件: Ras signaling pathway Ras signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D12181
D12181
|
Edasalonexent
| 1件: 113 113 |
66 |
MAPK12
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09639
D09639
|
Losmapimod
| 2件: 113 113, 222 |
67 |
MAPK12
| 31件: Rap1 signaling pathway Rap1 signaling pathway, Sphingolipid signaling pathway, Oocyte meiosis, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Thermogenesis, Retrograde endocannabinoid signaling, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10959
D10959
|
Neflamapimod
| 1件: 8 8 |
68 |
CCL2
| 5件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NOD-like receptor signaling pathway, TNF signaling pathway, Yersinia infection, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
69 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00742
D00742
|
Etanercept
| 17件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298 |
70 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
71 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
72 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02597
D02597
|
Adalimumab
| 18件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 |
73 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
74 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
75 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
76 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
77 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
78 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| 6件: 28 28, 34, 51, 85, 227, 331 |
79 |
TNF
| 24件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, Sphingolipid signaling pathway, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |
80 |
TYK2
| 5件: Osteoclast differentiation Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis | D09970
D09970
|
Tofacitinib
| 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
81 |
TYK2
| 5件: Osteoclast differentiation Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis | D11817
D11817
|
Deucravacitinib
| 2件: 96 96, 97 |
82 |
CASR
| 2件: NOD-like receptor signaling pathway NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action | D03504
D03504
|
Cinacalcet
| 2件: 85 85, 238 |
83 |
CASR
| 2件: NOD-like receptor signaling pathway NOD-like receptor signaling pathway, Parathyroid hormone synthesis, secretion and action | D03505
D03505
|
Cinacalcet
| 2件: 85 85, 238 |